<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00878605</url>
  </required_header>
  <id_info>
    <org_study_id>CLIN-010-08F</org_study_id>
    <nct_id>NCT00878605</nct_id>
  </id_info>
  <brief_title>Development of A Novel Anti-Hyperglycemic Agent</brief_title>
  <official_title>Development of A Novel Anti-Hyperglycemic Agent</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VA Office of Research and Development</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>VA Office of Research and Development</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this clinical trial is to test the effectiveness and safety of a new
      anti-diabetes drug (Cyclo-Z) for the prevention and treatment of Type 2 diabetes. This study
      will determine dose-dependent efficacy and safety of this new drug for the treatment of human
      diabetes. The Food and Drug Administration has granted approval for the use of this
      investigational product to be used in a study [FDA approval (Investigational New Drug) IND #:
      61,897]. This new drug is thought to work by increasing the amount of zinc in your body,
      which in turn should improve your sugar metabolism. If this study successfully proves that
      Cyclo-Z is effective for the treatment of diabetes and is without significant side effects, a
      large, multi-center study of diabetic patients will then be performed.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We have demonstrated that a cyclic dipeptide Cyclo (his-pro) plus zinc (Cyclo-Z) treatment
      improved clinical conditions of diabetes in various animal models and a phase 1 clinical
      trial. The main objective of this study is to demonstrate that this product is safe and
      effective for the treatment of human diabetes.

      Research Plan This is a randomized, double blinded, placebo-controlled, and parallel study.
      In this study, we will recruit 120 hypoglycemic drug na ve type 2 diabetic patients and
      randomize them into 4 groups of 30 subjects each to compare the effects of a Cyclo-Z capsule
      containing Cyclo-His Pro (CHP) 0 (placebo), 3 mg (minimally effective), 9 mg (optimally
      effective), or 15 mg (no-additional effect) plus 20 mg zinc on diabetic symptoms in a 12-week
      trial period. The primary outcome of this study is improvement of hemoglobin A1c; secondary
      outcomes are fasting blood glucose, 2 hours postprandial glucose and glucose tolerance test.
      Safety will be assessed by the presence of severe adverse events (SAEs), adverse events
      (AEs), any changes of vital signs, physical exams, blood hematology, chemistry, liver, renal,
      thyroid function tests, urine analysis and zinc, copper levels.

      Clinical Significance The proposed study has a direct impact on veteran's healthcare service.
      The applicant has obtained two types of US and international patent approvals for preventing
      and treating human diabetes and obesity with Cyclo-Z. One patent application for Alzheimer's
      disease treatment has just been approved. These patent rights are now assigned to the DVA.
      Based on our background studies and observation we anticipate the proposed Phase 2a clinical
      trials will prove that Cyclo-Z treatment is safe and effective for the treatment of human
      diabetes and we will be able to present a new class of anti-diabetes drug to improve
      healthcare of both the VA diabetic patients and the general public.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Unable to reach accrual target.
  </why_stopped>
  <start_date>April 2010</start_date>
  <completion_date type="Actual">September 2013</completion_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hemoglobin A1C</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>% change HgbA1c from baseline to 12 weeks.</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">38</enrollment>
  <condition>Diabetes</condition>
  <arm_group>
    <arm_group_label>Cyclo-Z (minimally effective)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3mg CHP plus 20mg zinc containing gel capsule;</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cyclo-Z (maximally effective)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>9mg CHP plus 20mg zinc containing gel capsule;</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cyclo-Z (not additionally effective)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>15mg CHP plus 20mg zinc containing gel capsule</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (for CHP)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo capsules containing no zinc or CHP</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclo-Z</intervention_name>
    <description>Cyclo-Z is a cyclic dipeptide Cyclo (his-pro) plus zinc that may lower blood glucose</description>
    <arm_group_label>Cyclo-Z (minimally effective)</arm_group_label>
    <arm_group_label>Cyclo-Z (maximally effective)</arm_group_label>
    <arm_group_label>Cyclo-Z (not additionally effective)</arm_group_label>
    <other_name>CHP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo control</description>
    <arm_group_label>Placebo (for CHP)</arm_group_label>
    <other_name>Sugar pill manufactured to mimic Cyclo-Z</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. History of type 2 diabetes mellitus who are na ve to hypoglycemic treatment,
             inadequately controlled by diet and exercise alone or oral medications.

          2. Hemoglobin A1c level of 6.5 % to 8.0 % inclusive. Subjects not taking hypoglycemic
             drugs with HgbA1c of 6.0% to 6.5% must have a diagnosis of Diabetes Mellitus (DM).

          3. Fasting blood glucose levels reasonably stable for at least 2 months or during the
             two-week lead-in-period.

          4. Ethnicity: All ethnic groups.

          5. Gender: Both men and women.

          6. Female with reproductive potential must not be pregnant or lactating, and using
             reliable contraception methods.

          7. Age &gt;18 years old.

        Exclusion Criteria:

          1. Taking insulin.

          2. History of diabetic ketoacidosis or hyper osmolar non-ketotic coma.

          3. Diabetes Mellitus related end-organ damage:

               -  Evidence of diabetic autonomic and peripheral neuropathy

               -  Diabetic proliferative retinopathy, based on eye exam by ophthalmologist

               -  Diabetes nephropathy defined by &gt; 500 mg/24 hour urinary albumin excretion

          4. Any disease likely to limit life span and/or increase risks of interventions:

               -  Screening carotid B-mode ultrasound indicating clinically significant stenos in
                  the common carotid arteries requiring intervention by angioplasty or resection.

               -  Cancer treatment in the past 5 years, with the exception of cancers that have
                  been cured, and carry a good prognosis.

               -  Infectious disease: HIV positivity, active tuberculosis, or pneumonia.

          5. Cardiovascular disease:

               -  Hospitalization for treatment of heart disease in the past 12 months.

               -  New York Heart Association Functional Class &gt; 2.

               -  Left Bundle branch block on EKG.

               -  Third degree atrioventricular block on EKG.

               -  Uncontrolled hypertension with average systolic blood pressure of &gt; 160 mmHg on
                  two screening visits and diastolic blood pressure &gt; 95 mmHg on two screening
                  visit.

               -  Pulse rate &gt; 95 beats per minute on both screening visits.

               -  Stroke or transient ischemic attack in the past 12 months.

          6. Gastrointestinal disease:

               -  Chronic hepatitis or cirrhosis.

               -  Episode of alcoholic hepatitis or alcoholic pancreatitis.

               -  Inflammatory bowel disease requiring treatment in the past 12 months.

               -  Recent or significant abdominal surgery (e.g. gastrectomy, gastric bypass).

          7. Renal disease: Serum creatinine &gt; 1.5 mg/dL for men, and &gt; 1.4 mg/dL for women.

          8. Lung disease:

               -  Chronic obstructive airway disease or asthma requiring daily therapy.

               -  Use of home oxygen.

          9. Anemia: Hematocrit of &lt; 36.0% in men or &lt; 33% in women.

         10. Conditions or behaviors likely to affect the conduct of the study

               -  Unable or unwilling to give informed consent.

               -  Unable to communicate with the clinic staff.

               -  Unwilling to accept treatment assignment by randomization.

               -  Weight loss of &gt; 10% in the past 6 months.

               -  Unable to walk without any assisted device.

               -  Major psychiatric disorder which would impede conduct of the research.

               -  Excessive alcohol intake (more than 2 drinks/day)

         11. Medications

               -  Psychoactive agents such as Monoamine oxidase inhibitors and Antidepressive
                  agents (lithium, prozac, zoloft, serzone, paxil, effexor)

               -  Systemic use of glucocorticoids steroids within previous 6 weeks.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhaoping Li, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>VA Greater Los Angeles Healthcare System, West LA</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>VA Greater Los Angeles Healthcare System, West LA</name>
      <address>
        <city>West Los Angeles</city>
        <state>California</state>
        <zip>90073</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 7, 2009</study_first_submitted>
  <study_first_submitted_qc>April 8, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 9, 2009</study_first_posted>
  <results_first_submitted>December 17, 2014</results_first_submitted>
  <results_first_submitted_qc>January 26, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 11, 2015</results_first_posted>
  <last_update_submitted>January 26, 2015</last_update_submitted>
  <last_update_submitted_qc>January 26, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 11, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diabetes</keyword>
  <keyword>Cyclo-Z</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypoglycemic Agents</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Study recruitment commenced on June 1, 2009 under version 1.0 of the protocol, upon approval of the study by the IRB. The first participant was enrolled April 2010, and the last January 2013. Participants received either Cyclo-Z gel 3mg + 20mg zinc; Cyclo-Z gel 9 mg + 20mg zinc; Cyclo-Z gel 15mg + 20mg zinc or Placebo once daily for 12 weeks.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Arm 1</title>
          <description>Placebo control
Placebo: Placebo control
Participants received placebo tablet orally daily for 12 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Arm 2</title>
          <description>Active medication
Cyclo-Z: Cyclo-Z is a cyclic dipeptide Cyclo (his-pro) plus zinc that may lower blood glucose
Participants received Cyclo-Z gel 3mg + 20 mg zinc orally per day for 12 weeks.</description>
        </group>
        <group group_id="P3">
          <title>Arm 3</title>
          <description>Active medication efficacy dose
Cyclo-Z: Cyclo-Z is a cyclic dipeptide Cyclo (his-pro) plus zinc that may lower blood glucose
Participants received Cyclo-Z gel 9mg + 20 mg zinc orally per day for 12 weeks.</description>
        </group>
        <group group_id="P4">
          <title>Arm 4</title>
          <description>Active medication high dose
Cyclo-Z: Cyclo-Z is a cyclic dipeptide Cyclo (his-pro) plus zinc that may lower blood glucose
Participants received Cyclo-Z gel 15mg + 20 mg zinc orally per day for 12 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Placebo control
Placebo: Placebo control</description>
        </group>
        <group group_id="B2">
          <title>Cyclo-Z Gel 3mg + 20 mg Zinc</title>
          <description>Active medication
Cyclo-Z: Cyclo-Z is a cyclic dipeptide Cyclo (his-pro) plus zinc that may lower blood glucose</description>
        </group>
        <group group_id="B3">
          <title>Cyclo-Z Gel 9mg + 20 mg Zinc</title>
          <description>Active medication efficacy dose
Cyclo-Z: Cyclo-Z is a cyclic dipeptide Cyclo (his-pro) plus zinc that may lower blood glucose</description>
        </group>
        <group group_id="B4">
          <title>Cyclo-Z Gel 15mg + 20 mg Zinc</title>
          <description>Active medication high dose
Cyclo-Z: Cyclo-Z is a cyclic dipeptide Cyclo (his-pro) plus zinc that may lower blood glucose</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
            <count group_id="B2" value="10"/>
            <count group_id="B3" value="9"/>
            <count group_id="B4" value="9"/>
            <count group_id="B5" value="38"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58.7" lower_limit="18" upper_limit="80"/>
                    <measurement group_id="B2" value="61.9" lower_limit="18" upper_limit="80"/>
                    <measurement group_id="B3" value="63.4" lower_limit="18" upper_limit="80"/>
                    <measurement group_id="B4" value="59.5" lower_limit="18" upper_limit="80"/>
                    <measurement group_id="B5" value="60.8" lower_limit="18" upper_limit="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline Demographics</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Hemoglobin A1C</title>
        <description>% change HgbA1c from baseline to 12 weeks.</description>
        <time_frame>Baseline and Week 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo control
Placebo: Placebo control</description>
          </group>
          <group group_id="O2">
            <title>Cyclo-Z Gel 3mg + 20 mg Zinc</title>
            <description>Active medication
Cyclo-Z: Cyclo-Z is a cyclic dipeptide Cyclo (his-pro) plus zinc that may lower blood glucose</description>
          </group>
          <group group_id="O3">
            <title>Cyclo-Z Gel 9mg + 20 mg Zinc</title>
            <description>Active medication efficacy dose
Cyclo-Z: Cyclo-Z is a cyclic dipeptide Cyclo (his-pro) plus zinc that may lower blood glucose</description>
          </group>
          <group group_id="O4">
            <title>Cyclo-Z Gel 15mg + 20 mg Zinc</title>
            <description>Active medication high dose
Cyclo-Z: Cyclo-Z is a cyclic dipeptide Cyclo (his-pro) plus zinc that may lower blood glucose</description>
          </group>
        </group_list>
        <measure>
          <title>Hemoglobin A1C</title>
          <description>% change HgbA1c from baseline to 12 weeks.</description>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>12 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Arm 1</title>
          <description>Placebo control
Placebo: Placebo control</description>
        </group>
        <group group_id="E2">
          <title>Arm 2</title>
          <description>Active medication
Cyclo-Z: Cyclo-Z is a cyclic dipeptide Cyclo (his-pro) plus zinc that may lower blood glucose</description>
        </group>
        <group group_id="E3">
          <title>Arm 3</title>
          <description>Active medication efficacy dose
Cyclo-Z: Cyclo-Z is a cyclic dipeptide Cyclo (his-pro) plus zinc that may lower blood glucose</description>
        </group>
        <group group_id="E4">
          <title>Arm 4</title>
          <description>Active medication high dose
Cyclo-Z: Cyclo-Z is a cyclic dipeptide Cyclo (his-pro) plus zinc that may lower blood glucose</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Suicidal Ideation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic Reaction to Shellfish</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>This subject was terminated early and data was not analyzed due to inability to recruit and therefore small numbers of subjects to analyze leading to uninterpretable data.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Zhaoping Li, Section Chief</name_or_title>
      <organization>VA Greater Los Angeles Healthcare System</organization>
      <phone>310-268-3528</phone>
      <email>zhaoping.li@va.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

